Safety, Tolerability and Pharmacokinetics of AD16 Tablets in Adult Healthy Subjects After Single Administration

NCT05787028 | Completed Phase 1

• 1 other identifier: SCCIP-AD16-2018-01
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic characteristics of single administration of AD16 tablets in healthy adults under fasting conditions, and the secondary objective was to preliminarily evaluate the material balance of single administration of AD16 tablets in fasting conditions. The study is divided into two parts: preliminary test and formal test. The formal trial was a single-center, randomized, placebo-controlled, double-blind, dose-increasing study, with 5 dose groups (5mg, 10mg, 20mg, 30mg and 40mg, respectively). Ten subjects (male and female) were enrolled in each dose group, of which 8 received the experimental drug and 2 received placebo. Urine and fecal samples were collected in the 20mg dose group for material balance study.Urine and fecal samples were collected in the 20mg dose group for material balance study.

Conditions

Alzheimer's Disease

Outcome Measures

Primary Outcomes (16)

• Adverse events

  The number of adverse events

  day-7 to day3

• Serious adverse events

  The number of serious adverse events

  day-7 to day3

• Number of participants with abnormal laboratory test results

  Laboratory tests include Blood routine, blood biochemistry, coagulation function and urine routine

  Screening period (day-7 to day-2) and day3

• Number of participants with abnormal vital signs

  Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.

  day-7 to day3

• Number of participants with abnormal 12-lead electrocardiogram readings

  abnormal 12-lead electrocardiogram readings

  Screening period (day-7 to day-2) and day3

• Number of participants with abnormal physical examination findings

  The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.

  Screening period (day-7 to day-2) and day3

• Concomitant Medication

  Any concomitant medication

  up to day3

• Tmax of AD16

  Time to reach the maximum (peak) plasma concentration following drug administration

  day1 to day3

• Cmax of AD16

  Maximum (peak) plasma drug concentration

  day1 to day3

• t1/2z of AD16

  Elimination half-life (to be used in a one-compartment or noncompartmental model)

  day1 to day3

• AUC 0-∞ of AD16

  AUC 0-∞ is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time). area under curve(AUC)

  day1 to day3

• AUC 0-t of AD16

  AUC 0-t is defined as the concentration of drug from time zero to the last quantifiable concentration.area under curve(AUC)

  day1 to day3

• CL/F of AD16

  CL/F is defined as the ratio of total clearance(CL) to bioavailability(F). administration

  day1 to day3

• Vd/F of AD16

  Apparent volume of distribution after non-intravenous administration

  day1 to day3

• λz of AD16

  Terminal disposition rate constant/terminal rate constant

  day1 to day3

• Mean retention time（MRT ）of AD16

  Mean retention time from first dosing to t hours or mean retention time from first dosing to infinity

  day1 to day3

Secondary Outcomes (3)

• Ae

  day-3 to day3

• Fe0-t

  day-3 to day3

• Renal clearance

  day-3 to day3

Study Arms (2)

AD16

EXPERIMENTAL

The experimental group received AD16, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day.7 dosing cohorts will receive a single oral dose of AD16.

Drug: AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg

placebo

PLACEBO COMPARATOR

The placebo group received AD16 placebo, which was a tablet with a dosage form of 10mg/tablet. Take warm water orally on an empty stomach in the morning, once a day. 7 dosing cohorts will receive a single oral dose of AD16 placebo.

Drug: AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg

Interventions

AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg DRUG

Take one AD16 tablet in the morning

AD16

AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg DRUG

Participants will take a placebo pill matching AD16 once in the morning

placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects were aged 18-45 years (including boundary values), male and female.
• Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends).
• Have fully understood this study, voluntarily participated in it, and signed the Informed Consent.
• Subjects are able to communicate well with researchers and complete the study according to protocol.
• The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests.
• Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.

You may not qualify if:

• Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.
• The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results.
• A history of postural hypotension with frequent episodes.
• A history of frequent nausea or vomiting due to any cause.
• Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study.
• Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center.
• Previous drug abuse history or positive urine drug screening during screening period.
• Smokers who smoked more than 5 cigarettes a day in the 3 months before the test.
• Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period.
• Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day.
• Surgical procedures, transfusions of blood or blood components in the month prior to study screening.
• Blood loss or donation of more than 400 mL in the 2 months prior to screening.
• Participated in other clinical studies and took experimental drugs within 3 months prior to study screening.
• Study participants who had received any medication in the 28 days prior to screening.
• Pregnant or lactating women or women who have had unprotected sex within 14 days.

Sponsors & Collaborators

• South China Center For Innovative Pharmaceuticals: lead
• Xiangya Hospital of Central South University: collaborator

Study Sites (1)

The Central South University Xiang Ya Hospital

Changsha, China

Location

Related Publications (1)

• Peng D, Xu S, Zou T, Wang Y, Ouyang W, Zhang Y, Dong C, Li D, Guo J, Shen Q, Hu X, Zhou W, Li X, Qin Q. Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer's disease: a randomized phase 1 study. BMC Med. 2023 Nov 23;21(1):459. doi: 10.1186/s12916-023-03126-9.

  PMID: 37996817 DERIVED

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: A single-center, randomized, placebo-controlled, double-blind, dose-increasing study

Study Record Dates

• First Submitted: March 1, 2023
• First Posted: March 28, 2023
• Study Start: January 30, 2019
• Primary Completion: May 31, 2020
• Study Completion: May 31, 2020
• Last Updated: December 1, 2023

Record last verified: 2023-11

Locations

CN (1)